Trieu V, et al. - This study involved examination of patients who were given weekly docetaxel, platinum, and cetuximab (TPC) for relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN), with a focus on the response rate, progression-free survival (PFS) and overall survival (OS), and safety profile. In this patient populace, a treatment regimen comprising weekly docetaxel, cisplatin, and cetuximab was found to be effective. Response rates, PFS, and OS compared favorably with other combination chemotherapy treatments. Compared with regimens using less frequent, higher-dose chemotherapy schedules, substantially lower grade 4 toxicity rates were observed in this study.